Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors

This is a clinical practice guideline for patients with a diagnosis of non–small cell lung cancer (NSCLC). The guideline examines the molecular analysis of lung cancers that are required to guide epidermal growth factor receptor (EGFR)- and anaplastic lymphoma kinase (ALK)-directed therapies. The guideline provides recommendations on which patients and samples should be tested, and when and how testing should be performed. Outcomes of interest include response rate, disease control rate, time to disease progression, survival (progression free and median), and sensitivity, specificity, positive predictive value, and negative predictive value of tests for EGFR and ALK status or treatment response.